ArticleJournal of translational medicine2026
Dissecting the immunosuppressive microenvironment of LAMA3 + malignant cells and SPP1 + macrophages in esophageal squamous cell carcinoma using single-cell and spatial transcriptomics.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
- Radiotherapy for overcoming immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) exhibits pronounced tumor microenvironment (TME) heterogeneity, which contributes to tumor invasion, immune evasion, and resistance to therapy. However, the cellular and spatial mechanisms driving this heterogeneity remain incompletely understood.
methodsWe integrated single-cell RNA sequencing and spatial transcriptomics to characterize the cellular composition, spatial organization, and tumor–immune interactions within ESCC tissues. Ligand–receptor communication was inferred using NicheNet modeling, and functional roles of key genes were evaluated through in vitro assays.
resultsWe identified a LAMA3⁺ epithelial subpopulation enriched at the invasive tumor front, characterized by strong epithelial–mesenchymal transition (EMT) signatures and poor prognostic relevance. Tumor-enriched SPP1⁺ macrophages with M2-like phenotypes were also identified and associated with adverse clinical outcomes. Spatial analyses revealed close colocalization of LAMA3⁺ epithelial cells and SPP1⁺ macrophages, while NicheNet modeling indicated reciprocal ligand–receptor interactions that directly mediated the extracellular matrix, and promoted desmoplastic niche formation. This cooperative network restricted lymphocyte infiltration despite a high tumor mutational burden, leading to an immune-excluded microenvironment. Clinically, co-enrichment of LAMA3 and SPP1 predicted impaired responses to anti–PD-L1 therapy. Functional assays further confirmed that LAMA3 promotes tumor cell proliferation, migration, and invasion.
conclusionsOur study identifies a synergistic LAMA3–SPP1 axis that promotes desmoplastic remodeling and immune evasion in ESCC, suggesting a potential therapeutic target to improve immunotherapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.